Notícias

The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.

In the closing of the recent trading day, Amgen (AMGN) stood at $337.5, denoting a -2.05% move from the preceding trading day.

MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.

Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.

Nvidia, Visa and Microsoft lead the list of Wall Street's top Dow Jones stocks to buy now. Some other names might surprise you.

Amgen (NASDAQ:AMGN) executives said the company’s first-quarter performance supports its view that 2026 can serve as a “springboard year,” with growth products helping offset increased competition for the denosumab franchise and other losses of exclusivity. Speaking at a Goldman Sachs event, Peter

Investors may be asking whether Amgen's share price still offers value at current levels, or if most of the opportunity is already reflected in the price. Amgen's stock last closed at US$345.73, with returns of 5.3% over 7 days, 4.2% over 30 days, 5.5% year to date, 21.4% over 1 year, 70.8% over 3 years, and 68.7% over 5 years. Recent attention on Amgen has focused on its position in large cap biotechnology and how market participants are evaluating the balance between its growth prospects...

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

With a net profit margin of 20.96%, Amgen Inc. (NASDAQ:AMGN) is included among the 10 Most Profitable Dividend Stocks to Invest In Now. On June 5, Goldman Sachs lowered its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $389 from $425. It reiterated a Buy rating on the stock. The firm adjusted its model after Amgen disclosed […]

More than a simple climb, the drugmaker's stock re-rated on a growth story that somehow keeps getting bigger.

The biotech giant is bucking the market trend, but its real value for investors lies in a story that unfolds over years, not days.

Stock Market Today: The Dow Jones index rose Monday on Trump's latest Iran comments. Marvell stock surged on news that it'll join the S&P 500..

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

This new ranking also showcases tech giants Alphabet, Microsoft, Meta and Cisco, propelled by high scores for innovation, financial strength and AI readiness

The oldest stock index in the world is suffering from a severe case of split personality. This internal friction has triggered a mechanical phenomenon, the likes of which I cannot recall, at least to this degree.

Investors looking for the best tech ETF might be disappointed to discover that a lot of the Invesco QQQ ETF's portfolio isn't actually tech.

The phrase sounds almost impossible: a short squeeze involving index funds. After all, index funds are designed to be passive, rules-based buyers, not active traders caught on the wrong side of a position. Yet that is exactly the scenario Animal Spirits hosts Michael Batnick and Ben Carlson laid out on Episode 467, “The Biggest Short ... SpaceX IPO Could Create ‘The Biggest Short Squeeze’ of All Time on Index Funds. Here’s How That Happens.

Amgen stock snapshot and recent performance Amgen (AMGN) is drawing attention after recent price moves, with the stock last closing at US$349.58. Over the past month it gained about 5.6%, while over the past 3 months it declined roughly 5.4%. See our latest analysis for Amgen. The recent 1-day share price return of 1.15% and 7-day return of 3.8% build on a 30-day share price gain of 5.6%, while the 1-year total shareholder return of 24% and 3-year total shareholder return of about 75% point...

Amgen (AMGN) stock is at an interesting point right now. If you bet on it, you are betting on a company that's growing reasonably, is sustaining good cash flow and margin, has a low-debt to market capital structure, and is relatively cheaply valued. But is that enough.

Amgen Inc. (NASDAQ:AMGN) is one of the best cheap stocks to buy for beginners. Amgen Inc. (NASDAQ:AMGN) announced on June 1 that the European Commission granted marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for the treatment of adults with extensive-stage small cell lung cancer who require systemic therapy following disease progression on or after first-line […]

Quantinuum’s IPO grabbed headlines, but its first trading day showed both excitement and caution. How can investors approach QNT stock after its Wall Street debut?

Amgen recently received European Commission approval for IMDYLLTRA (tarlatamab) to treat adults with extensive-stage small cell lung cancer after platinum-based chemotherapy and presented fresh Phase 3 and real-world data on UPLIZNA and TAVNEOS at the EULAR 2026 Congress, reinforcing their safety and disease-control profiles in rare autoimmune conditions. Together, the new oncology authorization and autoimmune data highlight Amgen’s growing presence in high unmet-need niches, where...

J&J faces Stelara erosion, China MedTech pressure and talc litigation, but targets $100B revenues and faster growth in 2026.

Amgen (NASDAQ:AMGN) executives used a Jefferies investor conference appearance to emphasize the company’s first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide. Peter Griffith, executive vice president and chief financial

Even without its metabolic business, management argues Eli Lilly (LLY) would be one of the fastest-growing pharmaceutical companies in the industry. This is not a single-product story. The company's immunology, oncology, and neuroscience medicines collectively grew by 160%, showing the depth of its R&D engine.

(Bloomberg) -- Quantinuum Inc., a quantum computing company backed by Honeywell International Inc., opened 13% above its listing price after raising $1.68 billion in an upsized US initial public offering.Most Read from BloombergGlazer Family Members Study Manchester United Stake SaleRepublican-Led House Votes to Stop Iran War, Rebuking TrumpTrump Begins Rebuilding His Tariff Wall, Citing Forced LaborBroadcom Slides by Most in More Than a Year on AI Outlook MissStock Buyers Step In to Lift Dow Av

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HON will own a large stake in Quantinuum following the IPO.

Stock Market Today: The Dow Jones index rose Thursday ahead of jobless claims. Broadcom and CrowdStrike plunged on earnings.

Investors may want to keep an eye on June 3 as Quantinuum is set to price its IPO and make a big move toward its Wall Street debut.